[go: up one dir, main page]

SG11201811151PA - Extracellular vesicle comprising a fusion protein having fc binding capacity - Google Patents

Extracellular vesicle comprising a fusion protein having fc binding capacity

Info

Publication number
SG11201811151PA
SG11201811151PA SG11201811151PA SG11201811151PA SG11201811151PA SG 11201811151P A SG11201811151P A SG 11201811151PA SG 11201811151P A SG11201811151P A SG 11201811151PA SG 11201811151P A SG11201811151P A SG 11201811151PA SG 11201811151P A SG11201811151P A SG 11201811151PA
Authority
SG
Singapore
Prior art keywords
international
evs
pct
extracellular vesicle
fusion protein
Prior art date
Application number
SG11201811151PA
Inventor
Oscar WIKLANDER
André Görgens
Dhanu Gupta
Original Assignee
Evox Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evox Therapeutics Ltd filed Critical Evox Therapeutics Ltd
Publication of SG11201811151PA publication Critical patent/SG11201811151PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Abstract

Fcbinder domain Exosomal protein 'Lipid bilayer () INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 January 2018 (25.01.2018) WIPO I PCT IiiimmoimiolollmonoloommonummomovoimIE (10) International Publication Number WO 2018/015535 Al (51) International Patent Classification: A61K 39/395 (2006.01) (21) International Application Number: PCT/EP2017/068476 (22) International Filing Date: 21 July 2017 (21.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1612643.5 21 July 2016 (21.07.2016) GB (71) Applicant: EVOX THERAPEUTICS LTD [GB/GB]; 2nd Floor, King Charles House, Park End Street, Oxford OX1 1JD (GB). (72) Inventors: WIKLANDER, Oscar; Greta Garbos vag 21B, 16940 Solna (SE). GORGENS, Andre; Domarvagen 18, Huddinge, SE-14162 (SE). GUPTA, Dhanu; Myrstuguva- gen 147, Varby, Huddinge, 143 32 Stockholm (SE). (74) Agent: COOLEY (UK) LLP; Dashwood, 69 Old Broad Street, London, Greater London EC2M 1QS (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) = (54) Title: EXTRACELLULAR VESICLE COMPRISING A FUSION PROTEIN HAVING FC BINDING CAPACITY (57) : The present invention pertains to extracellular vesicle (EV) therapeutics, wherein the EVs are coated with proteins containing Fc domains (such as antibodies) for i.a. targeting and therapeutic applications. The coating of EVs is achieved through inventive protein engineering of EV polypeptides. The present invention thus relates to methods for coating of EVs, EVs per se, as well as pharmaceutical compositions and medical applications of such EVs coated with Fc containing proteins. Lumen Extracetlular vesicle Figure 1 W O 20 18/0 155 35 Al
SG11201811151PA 2016-07-21 2017-07-21 Extracellular vesicle comprising a fusion protein having fc binding capacity SG11201811151PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1612643.5A GB2552473A (en) 2016-07-21 2016-07-21 Surface decoration of extracellular vesicles
PCT/EP2017/068476 WO2018015535A1 (en) 2016-07-21 2017-07-21 Extracellular vesicle comprising a fusion protein having fc binding capacity

Publications (1)

Publication Number Publication Date
SG11201811151PA true SG11201811151PA (en) 2019-01-30

Family

ID=56894359

Family Applications (4)

Application Number Title Priority Date Filing Date
SG11201811152YA SG11201811152YA (en) 2016-07-21 2017-07-21 Uses of extracellular vesicle comprising a fusion protein having fc binding capacity
SG10202100597TA SG10202100597TA (en) 2016-07-21 2017-07-21 Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity
SG11201811151PA SG11201811151PA (en) 2016-07-21 2017-07-21 Extracellular vesicle comprising a fusion protein having fc binding capacity
SG10202100598RA SG10202100598RA (en) 2016-07-21 2017-07-21 Uses of Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG11201811152YA SG11201811152YA (en) 2016-07-21 2017-07-21 Uses of extracellular vesicle comprising a fusion protein having fc binding capacity
SG10202100597TA SG10202100597TA (en) 2016-07-21 2017-07-21 Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202100598RA SG10202100598RA (en) 2016-07-21 2017-07-21 Uses of Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity

Country Status (12)

Country Link
US (3) US20230181757A1 (en)
EP (3) EP3487528B1 (en)
JP (4) JP7254016B2 (en)
KR (2) KR20190032479A (en)
CN (2) CN109689097B (en)
AU (2) AU2017300035A1 (en)
BR (2) BR112019001099A2 (en)
CA (2) CA3031183A1 (en)
GB (1) GB2552473A (en)
MX (2) MX2019000861A (en)
SG (4) SG11201811152YA (en)
WO (2) WO2018015535A1 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013540757A (en) 2010-09-24 2013-11-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド Nanostructured gel with the ability to control the release of encapsulated agent
GB2552774A (en) * 2016-07-12 2018-02-14 Evox Therapeutics Ltd EV-Mediated delivery of binding protein-small molecule conjugates
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
US11020410B2 (en) 2017-02-03 2021-06-01 The Brigham And Women's Hospital, Inc. Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
EP3664830A4 (en) 2017-08-07 2020-07-01 The Regents of the University of California PLATFORM FOR GENERATING SAFE CELL THERAPEUTICS
GB201717446D0 (en) * 2017-10-24 2017-12-06 Evox Therapeutics Ltd Affinity purification of engineering extracellular vesicles
GB201804291D0 (en) * 2018-03-16 2018-05-02 Evox Therapeutics Ltd Cell-mediated exosome delivery
EP3773478A1 (en) 2018-04-04 2021-02-17 Alivio Therapeutics, Inc. Self-assembled gels for controlled delivery of biologics and methods of making thereof
CN110655585A (en) * 2018-06-28 2020-01-07 中央研究院 Synthetic polypeptides and their uses
WO2020018932A1 (en) * 2018-07-20 2020-01-23 The Board Of Trustees Of The Leland Stanford Junior University Soluble polypeptides and methods of using same for inhibiting leukemia inhibitory factor activity
GB201812992D0 (en) 2018-08-09 2018-09-26 Univ Greenwich Liposomes
US12146238B2 (en) 2018-08-14 2024-11-19 Evercyte Gmbh Target-specific extracellular vesicles
CN108998402B (en) * 2018-08-28 2020-05-29 江南大学 A kind of recombinant Bacillus subtilis and its construction method and application
WO2020051507A1 (en) 2018-09-06 2020-03-12 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
CA3116327A1 (en) 2018-10-19 2020-04-23 Ohio State Innovation Foundation Nano-engineered therapeutic stealth cells
KR20210081362A (en) * 2018-10-19 2021-07-01 오하이오 스테이트 이노베이션 파운데이션 Extracellular vesicles for targeted therapy against bone marrow-derived suppressor cells
KR20210082186A (en) * 2018-10-19 2021-07-02 오하이오 스테이트 이노베이션 파운데이션 Nanocarriers for Pulmonary Inflammation Therapy
US20210386868A1 (en) * 2018-11-16 2021-12-16 Evox Therapeutics Ltd Extracellular vesicles for replacement of urea cycle proteins & nucleic acids
BR112021012647A2 (en) * 2018-12-27 2021-09-14 Akeso Biopharma, Inc ANTIBODY, ISOLATED POLYPEPTIDE, ISOLATED POLYNUCLEOTIDE, VECTOR, HOST CELL, METHODS FOR PREPARING THE ANTIBODY AND FOR THE PREVENTION AND/OR TREATMENT AND/OR adjuvant TREATMENT AND/OR DIAGNOSIS OF A DISEASE, ANTIBODY CONJUGATE, MULTISPECIFIC ANTIBODY, FUSION PROTEIN, PHARMACEUTICAL COMPOSITION, KIT, ANTIBODY USES, IN VIVO OR IN VITRO METHOD, HYBRIDOMA CELL AND MONOCLONAL ANTIBODY
KR20210142097A (en) * 2019-02-04 2021-11-24 코디악 바이오사이언시즈, 인크. Membrane protein scaffold for exosome manipulation
CN113924126A (en) * 2019-05-06 2022-01-11 托马斯·马尔科姆 Low-immunity nanovesicle delivery system tailored for cancer tumors
JP2022536364A (en) * 2019-06-13 2022-08-15 ザ ジェネラル ホスピタル コーポレイション Engineered human endogenous virus-like particles and methods of their use for delivery to cells
WO2020249757A1 (en) * 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
CN114269360A (en) * 2019-06-21 2022-04-01 恩特莱科索生物治疗公司 Platforms, compositions and methods for therapeutic delivery
CN116171163A (en) * 2019-08-06 2023-05-26 俄亥俄州国家创新基金会 therapeutic extracellular vesicles
EP3973969A4 (en) * 2019-09-02 2023-07-12 Kyungpook National University Industry-Academic Cooperation Foundation COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER USING IL-2 EXTRACELLULAR SURFACE EXPRESSION VESICLES AS AN ACTIVE AGENT
CN112941028A (en) * 2019-12-09 2021-06-11 上海细胞治疗集团有限公司 Nano antibody gene modified mesenchymal stem cell and preparation method and application thereof
AU2021215935A1 (en) 2020-02-05 2022-08-25 Diadem Biotherapeutics Inc. Artificial synapses
US20230149319A1 (en) * 2020-04-13 2023-05-18 City Of Hope Cell-receptor targeted exosomes
CN111544453B (en) * 2020-04-27 2021-01-22 高连如 Mixed stem cell injection containing three angiogenesis attributes and preparation method thereof
CN111560352B (en) * 2020-06-02 2023-03-24 新疆农业大学 Virus-like vesicle and preparation method and application thereof
CN111905105B (en) * 2020-07-02 2023-05-05 华南师范大学 A kind of protein nano-medicine for cancer targeted therapy and preparation method thereof
CN112111513A (en) * 2020-07-17 2020-12-22 深圳市第二人民医院 Preparation method of novel coronavirus vaccine based on exosome platform
WO2022020800A2 (en) 2020-07-24 2022-01-27 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
CN113967254B (en) * 2020-08-04 2022-08-12 华南理工大学 Cell membrane-coated nano-aptamers for multispecific antibody delivery and their applications
JP2023536665A (en) * 2020-08-05 2023-08-28 オハイオ・ステイト・イノベーション・ファウンデーション ADAPTER POLYPEPTIDES AND METHODS OF USE THEREOF
CN112285195B (en) * 2020-10-27 2021-08-10 江南大学 Characteristic glycoprotein marker of milk exosome and characteristic marker separation method of milk exosome
WO2022149779A1 (en) * 2021-01-11 2022-07-14 주식회사 엑소코바이오 Exosome comprising overexpressed fc receptor or portion thereof, and method for preparing same
KR102252325B1 (en) * 2021-01-14 2021-05-14 이장호 Production Methods of Immune-tolerant Extracellular Vesicles containing fetal-derived primal immunoglobulins
WO2022158836A1 (en) * 2021-01-21 2022-07-28 주식회사 엑소코바이오 Recombinant exosome comprising fc receptor or portion thereof to which target protein or peptide is fusible, and use thereof
WO2022219058A1 (en) * 2021-04-14 2022-10-20 Anjarium Biosciences Ag Fc-derived polypeptides
WO2022219075A2 (en) * 2021-04-14 2022-10-20 Anjarium Biosciences Ag Peptides, nanovesicles, and uses thereof for drug delivery
GB202107182D0 (en) * 2021-05-19 2021-06-30 Evox Therapeutics Ltd Nanoparticle delivery system for production of engineered extracellular vesicles
EP4355304A4 (en) * 2021-06-17 2025-04-30 Malcolm, Thomas TAILOR-MADE HYPOIMMUNE NANOVESICULAR DELIVERY SYSTEMS FOR CANCER TUMORS, HEREDITARY AND INFECTIOUS DISEASES
CN115770302A (en) * 2021-08-13 2023-03-10 南京大学 RNA delivery system and application thereof
CN113599516B (en) * 2021-08-16 2022-02-18 上海蒙彼利生物技术有限公司 Method for preparing exosome and application of pharmaceutical composition thereof in tissue repair
KR102577502B1 (en) * 2021-09-08 2023-09-13 주식회사 꿈랩 Plasmid platform for stable expression and delivery of biomolecules
CN113897387B (en) * 2021-10-09 2023-09-05 深圳市汉科生命工程有限公司 Preparation method and application of gene recombinant MSC (moving bed memory) with hair regeneration promoting function and exosome-like nanomaterial thereof
TWI893561B (en) * 2021-12-03 2025-08-11 中國醫藥大學 Production of exosomes and uses thereof
CN114107253B (en) * 2021-12-17 2024-03-15 复旦大学附属华山医院 A system and method for gene editing using engineered cells
CN114236113B (en) * 2021-12-21 2023-07-21 南京农业大学 A ready-to-use immunosensor for 2,4-D
US20250073350A1 (en) * 2022-01-04 2025-03-06 The Broad Institute, Inc. Compositions and methods for delivering cargo to a target cell
US20250231174A1 (en) * 2022-04-07 2025-07-17 The Regents Of The University Of Michigan Methods and devices for screening extracellular vesicles
WO2024064748A2 (en) * 2022-09-20 2024-03-28 North Carolina State University Compositions and methods related to exosomal delivery of therapeutic agents
CN116179582A (en) * 2022-09-27 2023-05-30 南京医事达生物科技有限公司 Preparation method and application of universal gene recombinant protein A affinity purification filler
CN117802045A (en) 2022-09-30 2024-04-02 北京恩康医药有限公司 Construction of an engineered extracellular vesicle and its application
CN115873905A (en) * 2022-11-15 2023-03-31 重庆医科大学附属儿童医院 Preparation method of a novel drug carrier of exosome-like GD2 nanobody targeting modification
WO2024225825A1 (en) * 2023-04-26 2024-10-31 주식회사 인엑소플랫 Recombinant extracellular vesicles containing immunoglobulin fc region or variant thereof and method for isolating extracellular vesicles using same
KR20240159543A (en) * 2023-04-28 2024-11-05 연세대학교 산학협력단 Method for isolating breast cancer-derived exosomes or extracellular vesicles
GB202307239D0 (en) 2023-05-15 2023-06-28 Evox Therapeutics Ltd Gene therapies for Phenylketonuria
CN119120376A (en) * 2023-07-10 2024-12-13 浙江大学医学院附属第一医院 Chimeric genetically engineered nanovesicle for clearing pathogenic antibodies and preparation method and application thereof
WO2025068572A2 (en) 2023-09-29 2025-04-03 Evox Therapeutics Limited Polypeptides comprising inteins for engineered evs
WO2025102257A1 (en) * 2023-11-15 2025-05-22 深圳先进技术研究院 Preparation method for uterus-targeting engineered extracellular vesicle and use of same
CN118725135B (en) * 2024-09-02 2025-02-07 中国科学院苏州纳米技术与纳米仿生研究所 Exosome modification methods
CN119019494B (en) * 2024-10-28 2025-02-07 广州飞来爱生命科技有限公司 Umbilical cord mesenchymal stem cells for treating myocardial infarction and preparation method and application thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059643A2 (en) * 1998-05-20 1999-11-25 Sdg, Inc. Liposomal delivery complex
US20040241176A1 (en) * 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
US20070128117A1 (en) * 2003-02-04 2007-06-07 Bracco International B.V. Ultrasound contrast agents and process for the preparation thereof
JP2007295929A (en) * 2006-04-05 2007-11-15 Geno Membrane:Kk Canine bsep gene
EP2198033A4 (en) * 2007-08-30 2011-05-25 Virexx Medical Corp Antigenic compositions and use of same in the targeted delivery of nucleic acids
EP2205264A4 (en) * 2007-09-24 2011-11-23 Univ Queensland MOLECULAR DELIVERY VESICLE
EP2419144B1 (en) * 2009-04-17 2019-08-07 Oxford University Innovation Limited Composition for delivery of genetic material
HUE033205T2 (en) * 2010-12-23 2017-11-28 Janssen Biotech Inc Active, protease-resistant antibody-FC mutant
EP2675474B1 (en) * 2011-02-15 2019-01-16 Vaxiion Therapeutics, LLC Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
GB201121070D0 (en) * 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
GB201121069D0 (en) 2011-12-07 2012-01-18 Isis Innovation Delivery system
JP6542197B2 (en) * 2013-04-12 2019-07-10 エヴォックス・セラピューティクス・リミテッド Therapeutic delivery vesicles
WO2015002956A1 (en) * 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
US10538570B2 (en) * 2013-09-30 2020-01-21 Northwestern University Targeted and modular exosome loading system
EP3057662A4 (en) 2013-10-17 2017-03-29 Children's Hospital Los Angeles Antibody dependent exosome therapy
WO2015143113A1 (en) * 2014-03-20 2015-09-24 Barb Ariel Cohen Preparations of derived extracellular vesicles, assays, and methods to modify therapeutic outcomes using such preparations
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles

Also Published As

Publication number Publication date
CN109689097A (en) 2019-04-26
EP3487528B1 (en) 2023-08-30
US11236143B2 (en) 2022-02-01
CN109689098A (en) 2019-04-26
CN109689097B (en) 2023-01-03
BR112019001099A2 (en) 2019-06-25
KR20190032480A (en) 2019-03-27
EP4299137A3 (en) 2024-04-10
SG11201811152YA (en) 2019-01-30
EP4299137A2 (en) 2024-01-03
JP7140743B2 (en) 2022-09-21
JP2019524745A (en) 2019-09-05
AU2017299214A1 (en) 2019-02-07
US20220098267A1 (en) 2022-03-31
KR20190032479A (en) 2019-03-27
AU2017300035A1 (en) 2019-02-07
JP2019523407A (en) 2019-08-22
JP7254016B2 (en) 2023-04-07
MX2019000861A (en) 2019-09-04
BR112019001108A2 (en) 2019-07-02
SG10202100597TA (en) 2021-02-25
CA3031186A1 (en) 2018-01-25
EP3487529A1 (en) 2019-05-29
KR102636776B1 (en) 2024-02-15
EP3487528A1 (en) 2019-05-29
WO2018015539A1 (en) 2018-01-25
US20200109183A1 (en) 2020-04-09
GB2552473A (en) 2018-01-31
SG10202100598RA (en) 2021-02-25
WO2018015535A1 (en) 2018-01-25
GB201612643D0 (en) 2016-09-07
JP2022117998A (en) 2022-08-12
US20230181757A1 (en) 2023-06-15
JP2023026440A (en) 2023-02-24
CA3031183A1 (en) 2018-01-25
MX2019000863A (en) 2019-09-04

Similar Documents

Publication Publication Date Title
SG11201811151PA (en) Extracellular vesicle comprising a fusion protein having fc binding capacity
SG11201811150WA (en) Ev-mediated delivery of binding protein-small molecule conjugates
SG11201909949XA (en) Targeted immunotolerance
SG11201810116VA (en) Exosomes comprising therapeutic polypeptides
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201811148SA (en) Cell penetrating peptide (cpp)-mediated ev loading
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201908919XA (en) Combination therapies targeting pd-1, tim-3, and lag-3
SG11201811549UA (en) Boronic acid derivatives and therapeutic uses thereof
SG11201809082WA (en) Nlrp3 modulators
SG11201811184UA (en) Lag -3 binding members
SG11201805442XA (en) Compositions and methods related to multimodal therapeutic cell systems for immune indications
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201907023UA (en) Method of reducing neutropenia
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201811706RA (en) Process for the preparation of microcapsules
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201810801QA (en) Brain delivery protein
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201808686VA (en) Synthesis of indazoles